Breaking Finance News

Oppenheimer downgraded Alcobra Ltd (NASDAQ:ADHD) from Outperform to Perform in a report released today.

Yesterday Alcobra Ltd (NASDAQ:ADHD) traded -53.64% lower at $2.09. The company’s 50-day moving average is $4.83 and its 200-day moving average is $4.53. The last stock close price is down -52.77% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,624,270 shares of the stock were exchanged, up from an average trading volume of 92,709

Oppenheimer has downgraded Alcobra Ltd (NASDAQ:ADHD) from Outperform to Perform in a report released on Thursday September 29, 2016.

Previously on 9/12/2016, WBB Securities reported about Alcobra Ltd (NASDAQ:ADHD) lowered the target price from $5.00 to $4.00. At the time, this indicated a possible downside of -0.17%.

See Chart Below

Alcobra Ltd (NASDAQ:ADHD)

Alcobra Ltd has a 52 week low of $2.00 and a 52 week high of $8.78 The company’s market cap is currently $0.

Also covering Alcobra Ltd's target, a total of 7 brokerages have issued a research note on the stock. The consensus target price is $12.71 with 3 equity analysts rating the company a strong buy, three brokerages rating the company a buy, zero analysts rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Alcobra Ltd (NASDAQ:ADHD)

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.